Artiva Biotherapeutics, Inc.
ARTVHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. With a market capitalization of $385.3M, it sits in small-cap territory. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Market Cap
$385.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.82
EPS (TTM)
$-3.55
EPS (Fwd)
$-2.81
ROE
-67.9%
ROA
-38.7%
Cash
$86.8M
Total Debt
$10.3M
Free CF
-$49.0M
52W Change
308.8%
Annual Financials
Cash vs Debt
Artiva Biotherapeutics, Inc. holds $86.8M in cash against $10.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$49.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -67.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $4.9M (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, ARTV has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ARTV.